Barriers to accessing malaria treatment amongst school-age children in rural Malawi.
Case management
Health care access
School-age children
Universal health care
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
06 Sep 2023
06 Sep 2023
Historique:
received:
10
11
2022
accepted:
29
08
2023
medline:
8
9
2023
pubmed:
7
9
2023
entrez:
6
9
2023
Statut:
epublish
Résumé
Over the last two decades, many countries have moved from malaria control toward malaria elimination. However, some sub-Saharan African countries, like Malawi, have recently seen a reversal in malaria control progress with reported increases in confirmed malaria cases. This may be the result of inadequate access to effective malaria control interventions by key population groups that perpetuate transmission. This study aimed to assess the barriers to accessing malaria treatment among school-aged children (SAC) in Malawi. A qualitative study was conducted between September and October 2020, where data were gathered in rural Malawi using free-listing interviews, key-informant interviews, semi-structured interviews and focus group discussions. Purposively sampled participants included SAC, parents of SAC, health workers and key stakeholders at community and district levels. Interviews were digitally recorded and transcribed verbatim. Data were organized using NVivo 12 software and analysed using the thematic method. The study recruited 252 participants, with 156 being SAC, equally divided between boys and girls. Health system barriers to malaria treatment included long waiting hours and queues at clinics, frequent stock-outs of medical supplies, and travel time to the facility. Provider barriers included negative attitude and limited service hours. Individual and cultural barriers included fear of malaria tests and beliefs associating witchcraft as the best treatment for malaria. In addition, COVID-19-related barriers included the inability to follow preventive measures, a shift in focus from malaria to COVID-19, and fear of contracting COVID-19 and/or being tested for COVID-19 at the facility. This study shows most of the barriers to accessing malaria treatment among SAC are similar to those experienced by other population groups. Furthermore, COVID-19 adversely affected SAC's access to treatment. Interventions that support SAC access to prompt diagnosis and treatment are urgently needed to improve the effective control of malaria.
Sections du résumé
BACKGROUND
BACKGROUND
Over the last two decades, many countries have moved from malaria control toward malaria elimination. However, some sub-Saharan African countries, like Malawi, have recently seen a reversal in malaria control progress with reported increases in confirmed malaria cases. This may be the result of inadequate access to effective malaria control interventions by key population groups that perpetuate transmission. This study aimed to assess the barriers to accessing malaria treatment among school-aged children (SAC) in Malawi.
METHODS
METHODS
A qualitative study was conducted between September and October 2020, where data were gathered in rural Malawi using free-listing interviews, key-informant interviews, semi-structured interviews and focus group discussions. Purposively sampled participants included SAC, parents of SAC, health workers and key stakeholders at community and district levels. Interviews were digitally recorded and transcribed verbatim. Data were organized using NVivo 12 software and analysed using the thematic method.
RESULTS
RESULTS
The study recruited 252 participants, with 156 being SAC, equally divided between boys and girls. Health system barriers to malaria treatment included long waiting hours and queues at clinics, frequent stock-outs of medical supplies, and travel time to the facility. Provider barriers included negative attitude and limited service hours. Individual and cultural barriers included fear of malaria tests and beliefs associating witchcraft as the best treatment for malaria. In addition, COVID-19-related barriers included the inability to follow preventive measures, a shift in focus from malaria to COVID-19, and fear of contracting COVID-19 and/or being tested for COVID-19 at the facility.
CONCLUSIONS
CONCLUSIONS
This study shows most of the barriers to accessing malaria treatment among SAC are similar to those experienced by other population groups. Furthermore, COVID-19 adversely affected SAC's access to treatment. Interventions that support SAC access to prompt diagnosis and treatment are urgently needed to improve the effective control of malaria.
Identifiants
pubmed: 37674177
doi: 10.1186/s12936-023-04695-z
pii: 10.1186/s12936-023-04695-z
pmc: PMC10481490
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258Subventions
Organisme : NIAID NIH HHS
ID : U19 AI089683
Pays : United States
Organisme : NIH HHS
ID : U19AI089683
Pays : United States
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Hum Resour Health. 2022 Jul 15;20(1):58
pubmed: 35840965
BMC Health Serv Res. 2019 Oct 22;19(1):735
pubmed: 31640676
Malar J. 2017 Nov 09;16(1):456
pubmed: 29121931
Am J Trop Med Hyg. 2012 Nov;87(5 Suppl):54-60
pubmed: 23136278
Malar J. 2018 Oct 17;17(1):369
pubmed: 30333022
BMJ Glob Health. 2020 Jan 14;5(1):e001666
pubmed: 32133163
Malar J. 2015 Sep 15;14:344
pubmed: 26370361
Malar J. 2009 Oct 28;8:243
pubmed: 19863788
BMC Int Health Hum Rights. 2010 Nov 24;10:29
pubmed: 21106099
Malar J. 2018 Nov 28;17(1):440
pubmed: 30486839
Malar J. 2018 Aug 22;17(1):305
pubmed: 30134987
Sci Rep. 2020 Jun 1;10(1):8907
pubmed: 32483161
BMC Health Serv Res. 2021 Aug 10;21(1):788
pubmed: 34376219
J Glob Health. 2019 Jun;9(1):010807
pubmed: 31263552
Am J Trop Med Hyg. 2015 May;92(5):933-940
pubmed: 25802438
Malar J. 2017 Aug 7;16(1):318
pubmed: 28784129
Malar J. 2021 May 24;20(1):233
pubmed: 34030711
Malar J. 2016 Feb 29;15:127
pubmed: 26928321
Malar J. 2016 Nov 22;15(1):563
pubmed: 27876046
Am J Trop Med Hyg. 2019 Feb;100(2):287-295
pubmed: 30526747
Int J Health Geogr. 2009 Mar 06;8:13
pubmed: 19267903
Malar J. 2017 Jan 23;16(1):40
pubmed: 28114942
Int J Infect Dis. 2020 May;94:151-153
pubmed: 32344326
Lancet Infect Dis. 2021 Nov;21(11):1568-1578
pubmed: 34146476
Malar J. 2019 Jul 30;18(1):260
pubmed: 31362736
Trop Med Infect Dis. 2020 Jun 19;5(2):
pubmed: 32575405
PLoS One. 2016 Jul 12;11(7):e0158331
pubmed: 27403877
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Int Health. 2019 Mar 1;11(2):143-149
pubmed: 30265330
Malar J. 2016 Oct 24;15(1):521
pubmed: 27776549
PLoS One. 2016 Jun 09;11(6):e0156717
pubmed: 27281028
Malar J. 2018 Nov 14;17(1):423
pubmed: 30428916
Malar J. 2010 Nov 11;9:320
pubmed: 21070644
Int J Equity Health. 2013 Mar 11;12:18
pubmed: 23496984
Malar J. 2017 Oct 18;16(1):419
pubmed: 29047388
Nat Med. 2020 Sep;26(9):1411-1416
pubmed: 32770167
Malar J. 2009 Sep 24;8:219
pubmed: 19778433
Nat Commun. 2017 Oct 26;8(1):1133
pubmed: 29074880
PLoS One. 2015 Jul 24;10(7):e0134061
pubmed: 26207758
Pharm Pract (Granada). 2019 Oct-Dec;17(4):1622
pubmed: 31897260
Healthcare (Basel). 2021 Sep 18;9(9):
pubmed: 34575007
Malar J. 2022 Feb 14;21(1):48
pubmed: 35164781
Prev Chronic Dis. 2021 Jan 14;18:E04
pubmed: 33444525
Lancet Infect Dis. 2021 Jan;21(1):59-69
pubmed: 32971006
Malar J. 2016 Mar 31;15:187
pubmed: 27036554
Malar J. 2012 Jan 11;11:18
pubmed: 22236395
Sci Rep. 2021 Mar 25;11(1):6905
pubmed: 33767384
Malar J. 2008 Nov 19;7:239
pubmed: 19019233
Malar J. 2021 Aug 11;20(1):339
pubmed: 34380494
Parasite Epidemiol Control. 2021 Aug 18;15:e00222
pubmed: 34632123